Who Experiences More Side Effects: Higher Risk of Side Effects: Women (higher rates than men) Starting at higher doses Rapid dose escalation History of GI issues (GERD, IBS) Slower metabolism Older age Lower Risk of Side Effects: Men (lower rates than women) Gradual dose escalation Prior GLP-1 exposure Following dietary recommendations Managing Side Effects Successfully: Diet Modifications: Foods to Emphasize: Lean proteins (chicken, fish, eggs) Non-starchy vegetables Clear broths and soups Crackers, toast (for nausea) Ginger (natural anti-nausea) Peppermint tea Foods to Avoid: Fatty, greasy foods (worsen nausea) Spicy foods (irritate GI tract) Large portions (harder to digest) Carbonated drinks (increase bloating) Alcohol (worsens nausea, dehydration) High-sugar foods (blood sugar swings) Eating Strategies: Small, frequent meals (5-6 times daily) Eat slowly, chew thoroughly Stop when satisfied (dont push to full) Stay upright after eating (prevents reflux) Dont drink large amounts with meals When to Contact Your Provider: Urgent (Call Immediately): Severe abdominal pain Persistent vomiting (cant keep fluids down) Signs of dehydration (dark urine, dizziness, confusion) Severe allergic reaction Vision changes Symptoms of pancreatitis Non-Urgent (Schedule Appointment): Side effects not improving after 4 weeks Want to discuss slowing dose escalation Questions about managing side effects Considering anti-nausea medication Weight loss plateau concerns Discontinuation Rates: Due to Side Effects: Semaglutide: 6.9% discontinue Tirzepatide: 6.2% discontinue Over 93% of patients tolerate well enough to continue Long-Term Safety: Semaglutide: On market since 2017 (8 years) Extensive real-world safety data SELECT trial: Actually reduced cardiovascular events (20% reduction) No new safety concerns with longer use Tirzepatide: On market since 2022 (3 years) Growing real-world safety data Clinical trials show excellent safety profile Cardiovascular outcomes trial ongoing Both medications appear safe for long-term use based on available evidence
Patients should only use medications prescribed by their healthcare professional and should not attempt to source unlicensed transdermal products, in line with MHRA guidance on buying medicines safely
04 Aftercare Guidance We share simple aftercare tips and talk through a treatment schedule if you want to continue building your results
It is the target for several FDA-approved antidiabetic medications called incretin mimetics: These incretin mimetics are glucagon-like peptide 1 (GLP-1) analogs that mimic the physiological action of GLP-1 and thereby potentiates the incretin effect in type 2 diabetic patients
Potency refers to the active ingredient in the correct dosage
We wanna make sure that we're following up
